Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00009906 · ClinicalTrials.gov registry record · Phase 3
Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 3
- Development phase
- 748
- Enrollment target
NCT00009906: Clinical Trial Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00009906 is a Phase 3 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 748 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00009906, a Phase 3 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 748 participants
- Enrollment target
Study Summary
Randomized phase III trial to compare the effectiveness of two different doses of STI571 in treating patients who have metastatic or unresectable gastrointestinal stromal tumor. STI571 may interfere with the growth of tumor cells and may be an effective treatment for cancer. It is not yet known which dose of STI571 is more effective in treating gastrointestinal stromal tumors.
Interventions
- DRUG Imatinib Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 748 participants |
| Start Date | 2000-12 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00009906
The ClinicalTrials.gov registry entry for NCT00009906 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 748 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imatinib Mesylate is the first listed.
NCT00009906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00009906 about?
NCT00009906 is a clinical study titled "Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor". Randomized phase III trial to compare the effectiveness of two different doses of STI571 in treating patients who have metastatic or unresectable gastrointestinal stromal tumor. STI571 may interfere with the growth of tumor cells and may be an effective treatment for cancer. It is not yet known whic...
What is the current status of trial NCT00009906?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 748 participants. The study started on 2000-12. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00009906?
The interventions under investigation include: Imatinib Mesylate (DRUG).
Who is sponsoring clinical trial NCT00009906?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.